Protease-activated receptor-2 (PAR2) in the airways

被引：103
|
作者：
Cocks, TM [1 ]
Moffatt, JD [1 ]
机构：
[1] Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia
来源：
PULMONARY PHARMACOLOGY & THERAPEUTICS | 2001年 / 14卷 / 03期
关键词：
protease-activated receptors (PARs); PAR2; inflammation; airways; trypsin; epithelium; mast cell tryptase; asthma; chronic obsturctive pulmonary disease;
D O I：
10.1006/pupt.2001.0285
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protease-activated receptors (PARs) act as sensors for active extracellular serine proteases, Since serine proteases like mast cell tryptase are associated with inflammatory processes, PARs may represent novel pharmacological targets in airway diseases like asthma and chronic obstructive pulmonary disease. However, our present understanding of the physiological roles of PARs is in its infancy. In this review we highlight evidence for the involvement of PARs in airway disease and propose that these novel receptors may play mainly protective roles, (C) 2001 Academic Press.
引用
收藏
页码：183 / 191
页数：9
相关论文
共 50 条
  • [1] Protease-activated Receptor-2 (PAR2) in Human Periodontitis
    Holzhausen, M.
    Cortelli, J. R.
    Araujo da Silva, V.
    Nobre Franco, G. C.
    Cavalca Cortelli, S.
    Vergnolle, N.
    [J]. JOURNAL OF DENTAL RESEARCH, 2010, 89 (09) : 948 - 953
  • [2] Protease-activated receptor-2 (PAR2) in cardiovascular system
    Bucci, M
    Roviezzo, F
    Cirino, G
    [J]. VASCULAR PHARMACOLOGY, 2005, 43 (04) : 247 - 253
  • [3] Does protease-activated receptor-2 (PAR2) influence muscle development and regeneration?
    Esfandouni, N. Taghavi
    Mackie, E.
    Pagel, C.
    [J]. NEUROMUSCULAR DISORDERS, 2015, 25 : S218 - S219
  • [4] Predictive value of protease-activated receptor-2 (PAR2) in cervical cancer metastasis
    He, Shengnan
    Xu, Meiquan
    Xiong, Zhen
    Hu, Ye
    Huo, Qin
    Lu, Jingxiao
    Lin, Yuntao
    Yang, Lan
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (03) : 1415 - 1424
  • [5] Toward Drugs for Protease-Activated Receptor 2 (PAR2)
    Yau, Mei-Kwan
    Liu, Ligong
    Fairlie, David P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (19) : 7477 - 7497
  • [6] Protease-Activated Receptor-2 (PAR2)-A Novel Therapeutic Target in Nonalcoholic Steatohepatitis (NASH)
    Shearer, Andrew M.
    Austin, Karyn
    Guha, Srijoy
    Nga Nguyen
    Looby, Richard
    Clappin, Allyson
    Baleja, James
    Covic, Lidija
    Kuliopulos, Athan
    [J]. HEPATOLOGY, 2014, 60 : 587A - 587A
  • [7] Pepducin - A Novel Protease-Activated Receptor-2 (par2) Inhibitor - Attenuates Experimental Pulmonary Hypertension
    Warburton, R.
    Kuliopulos, A.
    Wieschhaus, A.
    Kayyali, U. S.
    Toksoz, D.
    Fanburg, B. L.
    Preston, I. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [8] Protease activated receptor-2 (PAR2): possible target of phytochemicals
    Kakarala, Kavita Kumari
    Jamil, Kaiser
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2015, 33 (09): : 2003 - 2022
  • [9] Potent lipidated antagonists to protease-activated receptor 2 (PAR2)
    Boitano, Scott
    Hoffman, Justin
    Flynn, Andrea
    Sherwood, Cara L.
    Zhang, Zhenyu
    Patek, Renata
    Price, Theodore J.
    Vagner, Josef
    [J]. FASEB JOURNAL, 2016, 30
  • [10] Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin
    Shearer, Andrew M.
    Rana, Rajashree
    Austin, Karyn
    Baleja, James D.
    Nguyen, Nga
    Bohm, Andrew
    Covic, Lidija
    Kuliopulos, Athan
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (44) : 23188 - 23198
12345